Voya Investment Management LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 35.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,164,502 shares of the healthcare product maker's stock after selling 651,753 shares during the quarter. Voya Investment Management LLC owned approximately 0.07% of Abbott Laboratories worth $131,717,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. increased its holdings in Abbott Laboratories by 6.6% in the fourth quarter. Cape Investment Advisory Inc. now owns 1,236 shares of the healthcare product maker's stock worth $140,000 after buying an additional 76 shares during the last quarter. Capital Square LLC lifted its stake in shares of Abbott Laboratories by 2.7% in the 4th quarter. Capital Square LLC now owns 2,941 shares of the healthcare product maker's stock valued at $368,000 after purchasing an additional 77 shares during the last quarter. Cyrus J. Lawrence LLC increased its position in Abbott Laboratories by 9.0% during the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock worth $107,000 after buying an additional 79 shares during the last quarter. Jacobson & Schmitt Advisors LLC boosted its stake in shares of Abbott Laboratories by 2.9% during the 4th quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker's stock worth $320,000 after acquiring an additional 80 shares in the last quarter. Finally, LMG Wealth Partners LLC lifted its holdings in Abbott Laboratories by 3.8% in the 4th quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker's stock worth $244,000 after purchasing an additional 80 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.
Insider Activity at Abbott Laboratories
In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the sale, the executive vice president now owns 71,928 shares in the company, valued at $9,625,404.96. This represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,449 shares of company stock worth $15,463,316 over the last 90 days. Insiders own 0.46% of the company's stock.
Abbott Laboratories Price Performance
Shares of ABT stock traded up $0.67 during trading hours on Monday, hitting $129.52. 3,833,894 shares of the company's stock were exchanged, compared to its average volume of 6,064,275. The stock's 50-day moving average is $130.54 and its 200-day moving average is $122.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The stock has a market cap of $224.63 billion, a price-to-earnings ratio of 16.93, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80.
Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. As a group, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.82%. Abbott Laboratories's payout ratio is currently 30.61%.
Analyst Ratings Changes
Several analysts recently issued reports on the stock. Barclays upped their price objective on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. UBS Group upped their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Stifel Nicolaus lifted their target price on Abbott Laboratories from $135.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. Finally, The Goldman Sachs Group raised their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $142.59.
Read Our Latest Analysis on ABT
Abbott Laboratories Company Profile
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Stories
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
